Quris AI is pioneering a novel hybrid approach to drug safety prediction through its Bio-AI Clinical Prediction Platform. This innovative platform leverages advanced machine learning techniques to enhance the accuracy of predicting which drug candidates will be safe and effective for human use. By utilizing a unique method that involves testing drugs on miniaturized models known as Patients-on-a-Chip, Quris generates valuable data that is automatically tagged and used to train its classification algorithms. This approach aims to significantly reduce the high costs associated with drug development, where a staggering 89% of drugs fail during clinical trials.

The company is backed by a distinguished team of experts in machine learning, big data, genomics, and medical device development, including notable figures such as Moderna co-founder Robert Langer and Nobel Laureate Aaron Ciechanover. Quris AI is not only focused on technological innovation but also emphasizes a commitment to positive societal impact and robust environmental, social, and governance (ESG) standards. As they prepare for clinical testing of their first AI-based drug, Quris aims to address the critical challenges in the pharmaceutical industry that have yet to be effectively tackled by other AI-driven companies.

United States

Quris-AI is an artificial intelligence innovator that is disrupting drug development. Its machine-learning bio-platform better predicts which drug candidates will safely work in humans, avoiding tremendous costs of failed clinical trials. Quris-AI is led by a track-record team of top scientists and strategic investors. Its first AI-based drug is now prepping for clinical testing.

Quris AI

Company Details